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ABSTRACT
Objective: To critically examine the process of
multidisciplinary team (MDT) decision-making with a
particular focus on patient involvement.
Design: Ethnographic study using direct non-
participant observation of 35 MDT meetings and 37
MDT clinics, informal interviews and formal,
semistructured interviews with 20 patients and 9 MDT
staff members.
Setting: Three head and neck cancer centres in the
north of England.
Participants: Patients with a diagnosis of new or
recurrent head and neck cancer and staff members
who attend the head and neck cancer MDT.
Results: Individual members of the MDT often have a
clear view of which treatment they consider to be ‘best’
in any clinical situation. When disagreement occurs,
the MDT has to manage how it presents this difference
of opinion to the patient. First, this is because the MDT
members recognise that the clinician selected to
present the treatment choice to the patient may ‘frame’
their description of the treatment options to fit their
own view of best. Second, many MDT members feel
that any disagreement and difference of opinion in the
MDT meeting should be concealed from the patient.
This leads to much of the work of decision-making
occurring in the MDT meeting, thus excluding the
patient. MDT members seek to counteract this by
introducing increasing amounts of information about
the patient into the MDT meeting, thus creating an
‘evidential patient’. Often, only highly selected or very
limited information of this type can be available or
known and it can easily be selectively reported in order
to steer the discussion in a particular direction.
Conclusions: The process of MDT decision-making
presents significant barriers to effective patient
involvement. If patients are to be effectively involved in
cancer decision-making, the process of MDT decision-
making needs substantial review.
INTRODUCTION
Multidisciplinary team (MDT) working and
team decision-making is currently the stand-
ard of care in cancer treatment decision-
making and all patients with cancer should
have their treatment plan discussed in an
MDT.1 The MDT was introduced after the
‘Calman-Hine report’2 that was written as a
response to unaddressed variation in care
across the UK3 4 and an increasing weight of
evidence suggesting that those patients
treated in specialist cancer centres had
better outcomes than those who were not.5 6
MDT working is thought to improve cancer
staging accuracy,7 recruitment to clinical
trials,8 9 adherence to quality-of-care indica-
tors,10 patient satisfaction and time to treat-
ment.11 However, the introduction of MDT
working has not resulted in a demonstrable
improvement in cancer survival.12 Indeed,
although a treatment plan devised by an
MDT often differs from that of a single clin-
ician,13–15 whether or not it is a superior
decision is unclear. MDTs are also resource-
intensive: the meeting and the time taken to
prepare for it are time consuming.16 The
estimated cost of all UK MDT meetings is
£50 million a year for preparation and the
same amount again for attendance.17
It is ethically important to make good,
individualised healthcare decisions that
Strengths and limitations of this study
▪ This study is an in-depth ethnographic study of
team decision-making in head and neck cancer
and our findings may be applicable to other cir-
cumstances where team decision-making is used
(in cancer or other disease states).
▪ It is the first study to analyse transcribed audio-
recorded data from team meetings and clinic
appointments and provides a novel insight into
the challenges facing MDTs when involving
patients in decisions.
▪ Data were collected from only three centres in
the north of England and as such do not repre-
sent a broad view of multiple team and clinic
manifestations which may be present in other
centres.
▪ Some of the challenges described may have
been tackled in other departments by variations
in the structure of the team meeting and clinic.
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respond effectively to the needs of the patient. Using
decision aids to help share decisions with patients results
in improved patient knowledge, lower decisional conflict,
increased patient satisfaction with the decision-making
encounter and improved perception of risk.18 Well-
informed patients make different decisions to those who
are less well informed,19 may perceive risk in a different
way20 and adhere better to treatment.21 Doctors who do
not effectively involve patients in decisions about their
health may feel that they are working in the best interests
of the patient, but in fact may not arrive at a decision that
is right for that particular patient. When the treatment
priorities of patients and clinicians are compared in head
and neck cancer (HNC), they are invariably found not to
match22–26 and this finding is echoed in other
cancers.27 28 If the aim of the MDT meeting and clinic is
to make appropriate individualised treatment decisions,
then the values and preferences of the patient should be
central to the process. However, there is emerging evi-
dence that the process of MDT working presents barriers
to effective involvement of the patient in decision-
making.29 30 MDTs often struggle with how and when to
incorporate individual patient information such as treat-
ment preference into the discussion.31 32
Patients and clinicians face particular difficulties with
decision-making in HNC. Almost a third of patients with
HNC will die of their disease within 2 years, while treat-
ment may cause persistent and debilitating effects on
swallow, voice and quality of life. In order to achieve
cure of the disease, patients often need to trade-off
swallow or voice function; hence, treatment decision-
making in HNC is an excellent context for exploring
MDT decision-making. This article aims to critically
examine the process of MDT decision-making with a
particular focus on how the MDT decision-making
process involves patients.
METHODS
This qualitative study used non-participant observation
and semistructured interviews to critically examine how
decisions were made in the MDT (see figure 1). All data
were collected by one researcher (DWH). Non-partici-
pant observation enables the researcher to study
participants in their natural environment, and adds value
to retrospective accounts gleaned only through partici-
pant interviews which may provide idealised accounts of
events.33
Ethical approval
Ethical approval was gained from the NHS Research
Ethics Newcastle and North Tyneside 2 committee (ref-
erence 11/NE/0200) in September 2011. Prior to the
commencement of data collection in each centre, all
necessary local Research and Development governance
permissions were obtained.
Before interviews, written consent was obtained from
participants; however, for observations, a lengthy process
of informing potential participants about the study was
followed (with opportunity for questions and cooling
off) and then verbal consent.
Observations
The research was conducted in three HNC centres in the
north east of England. Non-participant observations of
35 MDT meetings and 37 MDT clinics were conducted,
and from these, 30 patients with HNC were sampled
(table 1). Patients were excluded from the study if they
did not understand written or spoken English or they did
not have the capacity to consent. The MDT meetings and
clinics were all audio-recorded and transcribed verbatim.
Detailed field notes were also made at the time of obser-
vation, then transcribed immediately afterwards.
Figure 1 Study flow chart. *MDT meeting between staff members: patient is discussed, imaging and pathology reviewed, but
patient is not present. +Clinic appointment between some members of the MDT and the patient, where treatment decision is
made. MDT, multidisciplinary team.
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Interviews
Semistructured interviews were conducted with patients
and staff (see table 1). In a semistructured interview, a
researcher has a topic guide with the topics of discussion
or specific questions,34 but the format allows the partici-
pant to talk in more depth on certain subjects. This
means that the resultant data are comparable, but rich
and in depth. The development of the interview guide
was iterative; as data collection continued, the content of
the guide evolved in order to explore emerging themes.
In total, 20 patients were interviewed between the treat-
ment decision and the commencement of treatment.
Four of these patients were interviewed again 9 months
following the completion of treatment. Semistructured
interviews were also conducted with nine MDT members
(five surgeons, two oncologists, one speech and language
Table 1 Details of included participants and data collection
Observation
Patients: group 1 Centre Age Tumour site MDT Clinic Int 1 Int 2
James Cain A 68 Pharynx 1 1 1 1
Frances Cotton A 82 Pharynx 1 1 x x
Philip Vase A 61 Parotid 1 1 x x
Fred Barnes A 71 Lip 1 1 x x
Deborah Dolphin A 54 Pharynx 1 1 1 x
Vincent Lowry A 80 Pharynx 1 1 x x
David Forcett A 72 Pinna 1 1 x x
Stanley Wright A 87 Pharynx 1 1 1 x
Daniel Carding A 64 Larynx 1 1 1 x
John Winton A 61 Larynx 1 1 1 x
Bobby Older A 52 Pharynx 1 1 x x
Samuel Black A 55 Pharynx 1 1 1 1
Keith Down A 62 Larynx 1 1 1 x
William Runman B 73 Pharynx 3 1 1 x
Andrew Driver B 49 Pharynx 1 1 1 x
Donna Childs B 52 Pharynx 1 1 1 x
David Jobling B 63 Larynx 1 1 x x
Sophie Leicester B 49 Larynx 1 1 x x
Edward Doman B 73 Mouth 3 1 1 x
Eric Francais B 65 Larynx 1 1 1 x
Gary Duck B 57 Pharynx 1 1 x x
Jean Dixon B 63 Pharynx 1 2 1 1
Jane Doe C 69 Pharynx 1 2 1 x
Margaret Brigstock C 81 Mandible 1 2 x x
Roy Dayson C 60 Pharynx 1 1 1 x
Dana O’Malley C 67 Pharynx 1 1 x x
Gary Nicholson C 46 Pharynx 1 2 x x
Tracey Burnham C 38 Larynx 1 1 x x
James Matfield C 70 Larynx 1 4 1 x
David Dale C 84 Larynx 1 1 x x
Kevin Hair A 82 Pharynx x x 1 x
David Newman A 57 Larynx x x 1 x
Frank Sunnyman A 52 Pharynx x x 1 x
Phil Gardener B 65 Larynx x x 1 x
Staff (interview only) Centre Role
Mr Red A ENT surgeon
Dr Brown A Oncologist
Mr Surton A Maxillofacial surgeon
Mrs Pope A Speech and Language
Therapist
Tessa Dark A Clinical Nurse Specialist
Mr Halifax B Maxillofacial surgeon
Mr Blaydon B ENT surgeon
Mr North B ENT surgeon
Dr Goodier C Oncologist
Int, interview; MDT, multidisciplinary team.
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therapist and one clinical nurse specialist; see table 1). In
addition to these formal interviews, through the course
of the observations, informal interviews with staff
members of the MDT also took place which, although
not audio-recorded, were incorporated into written field
notes. Pseudonyms were used for reporting data through-
out to protect the anonymity of respondents.
Sampling
Purposive sampling was used throughout the study in
order to build concepts and ask questions of the emer-
ging data. Data collection and analysis occurred in
tandem, and further sampling was guided by the emer-
ging analysis.35 Patients and staff members were sampled
with the aim of exploring, developing or challenging the
emerging concepts and themes from the prior analysis.
Sampling continued until a state of theoretical suffi-
ciency36 was achieved.
Analysis
The data were analysed by one researcher (DWH) fol-
lowing principles of constructivist grounded theory.37
First, line-by-line open coding was performed on a small
number of transcripts and from this, an initial coding
framework was produced. Following this, all transcripts
were coded using axial coding, based on the initial
coding framework. The emerging analysis was used to
guide further sampling and further development of the
coding framework; when the coding framework was
altered, all transcripts were recoded. The emerging
coding framework and analysis was discussed in depth
with BH and CE at regular intervals, and with the wider
research team. In line with constructivist grounded
theory, the codes used were conceptual, rather than
descriptive, and labels were derived completely from the
data, not predetermined. The coding was organised
using the NVivo version 9 computer package. Memos
were used to develop a deeper description of the codes
and the data, and allowed the development of theory
which again was used to guide further sampling.
RESULTS
In all centres studied, the MDT meeting was attended by
a range of medical specialities and allied healthcare pro-
fessionals, and took place before the patient was seen in
the MDT clinic. The patient was not present at the MDT
meeting; hence, it was a ‘backstage’ area38 where staff
members could talk more openly about the patient,
their treatment options and their prognosis. The aim of
the discussion was to reach a consensus on which treat-
ment or treatments were considered to be the ‘best’; this
treatment recommendation was then delivered to the
patient in the MDT clinic, a ‘frontstage’ area where the
patient is present (see figure 1). Many individual clini-
cians had their own strongly held view of what they feel
is ‘best’ in certain clinical situations:
In general head and neck there often isn’t an option;
you’ve got the best treatment that there’s an evidence
base for that…once you’ve decided on that option…that
is the truth as far as we know it…the patient’s decision…
may not be ‘I want radiotherapy, I want surgery’, it’s do
you want the best treatment we know of or not.
(Dr Brown, Oncologist, Interview)
Often, the members of the MDTagreed that one option
was clearly the ‘best’ treatment for a particular patient. If
this was the case, the option was usually delivered by a
member of the MDTas a single recommendation for treat-
ment to the patient in the MDT clinic. However, at other
times, such agreement did not occur; rather, different clini-
cians held different views about what was the ‘best’ option.
In this situation, although all options were presented to the
patient by a clinician, the clinician’s description of the
treatment options was often ‘framed’. Framing is where the
options are not presented in a balanced way, but with an
emphasis that makes it difficult for the patient to do any-
thing other than comply with the speaker’s assessment of
‘best’ or at least tend towards favouring one option over
another. The following data extract is an oncologist’s
description of radiotherapy given to a patient in clinic:
Dr Green: It’s a very accurate treatment. …You don’t feel
anything. You just lie there and then you go home again.
…But, the radiotherapy does cause some side effects and
they can be quite nasty. Obviously the aim of the radio-
therapy is to try and get rid of this cancer and to do that
we have to give quite big doses of the radiotherapy. …So
your skin on the outside will start getting red like it’s had
a sun burn-type reaction and on the inside it starts
getting red and inflamed as well. And that means that
you’ll start having problems like a sore throat and some
problems with your swallowing. …And that means
that you’ll need lots of support as you go through the
treatment.
(David Dale, Observation, MDT Clinic)
Here the emphasis on the positive aspects of the treat-
ment can be seen; comparisons were made to previous
experiences that are undoubtedly unpleasant and diffi-
cult, but certainly not overpowering. The next extract
is to a similar patient in a different clinic; the oncolo-
gist was explaining the process and side effects of
radiotherapy:
Dr Goodier: We need to spread it out over six weeks of
daily treatment. That means you coming up from home,
Monday to Friday, every day for six weeks with just gaps at
the weekend. …We would lie you on a couch on your
back, wide awake. …As the treatment goes through, your
body starts reacting to the radiation that we’re giving it.
…Everything becomes inflamed and sore. The outside of
your skin and the inside of your throat will all become
quite red and hot and sore and that’s why swallowing will
become very, very difficult—probably impossible. Even
swallowing your own saliva will be impossible by the time
you get to the end of that six weeks.
(Gary Nicholson, Observation, MDT Clinic)
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In both of these extracts, the patient had a choice
between treatment options. The comparison of these
data extracts demonstrates how the description of a
treatment option could have a fundamental effect over
the treatment choice made by the patient. It would be
understandable for the patient to choose the first
description, and turn down the second. This means a
doctor can offer choice (in that two options can be
described and offered), without offering properly
informed choice.
Presentation of treatment options
The MDT members regularly disagreed on which treat-
ment was best or felt that two or more treatment options
could equally be considered for an individual patient. A
difference of opinion may be due to varying interpreta-
tions of the clinical evidence or the research literature,
or alternative conceptualisations of how the ‘best’ treat-
ment can be defined. The following extract is from the
MDT meeting discussion about Samuel Belton, a
55-year-old man with a moderately sized (T2) cancer of
the tonsil. At this point in the discussion, some
members of the team felt that the patient should have a
major resection and reconstruction, whereas others felt
that he should have radical chemoradiotherapy:
Mr Surton [Maxillofacial surgeon]: So shall we see him
together
(Silence 10s)
Mr Jones [ENT surgeon]: Depends how you put it to the
patient isn’t it, you know!
Mr West [Plastic surgeon]: It’s one of these things, we’ve
done this before, and you see the patient, and you have
two people there, and you confuse the patient even
more. I think…
Tessa [Clinical Nurse Specialist]: It’s horrendous, I think
it is the worst thing you can do for a patient
Mr West: I agree. I think it’s a terrible thing
Tessa: Patients just don’t know, they just don’t know what
to do
Mr Surton: But are we not supposed to give the patient
choice?
Mr West: And if we can’t decide, I think it’s really unfair,
I know we’ve been here before and we’ve spoken about
it, but this is…
Tessa: Hey I’ve seen…, you know it’s picking up the
pieces afterwards, because they really cannot make that
decision.
(Samuel Belton, Observation, MDT Meeting, Centre A, 1
March 2012)
Importantly, this particular discussion did not centre
on the merits of the particular treatments: the individual
members had interpreted the available evidence and
come to different conclusions. Instead, the discussion
was about whether the MDT members should come to a
consensus in the MDT meeting or offer the options for
treatment to the patient.
In the discussion above, the MDT as a group had two
treatment options available for the patient. However,
individuals within the group disagreed on which option
was better. This led to difficulty in deciding who would
communicate the final view of the MDT to the patient.
Different clinicians may frame their description to their
own individual view of which is ‘best’, as previously
shown. In the extract above, this was acknowledged with
the comment from Mr Jones, ‘Depends how you put it
to the patient isn’t it, you know!’. MDT members are
aware of the effect of framing on the delivery of the
treatment recommendation(s) in the MDT clinic. The
following data are taken from observation of an MDT
meeting for Philip Vase discussing whether he should be
offered postoperative radiotherapy or not:
Dr Brown (oncologist): I’d give him radiotherapy but…
would you keep him under observation then?
Dr Yellow (oncologist): [nods]
Dr Brown: I think you would cause not really very much
morbidity [with radiotherapy], it’s so peripheral and so
lateral. So…if you want him treated, send him to me, if
you want him under observation, send him to Dr Yellow.
(Philip Vase, Observation, MDT meeting)
These data clearly demonstrate that the MDT
members acknowledged that framing exists. Thus, the
choice of who delivers the recommendation can become
a proxy for the recommendation itself. This not only
demonstrates the difficulties the MDT face when there is
more than one option but arguably undermines the
whole MDT decision process.
Uncertainty
The difference of opinion demonstrated by the case of
Samuel Belton above was seen by many members of the
MDT as something which should remain in the backstage
MDT meeting, and not be presented to the patient.
I really do not believe it’s fair to say to the patient,
“We’re quite uncertain, we don’t know what to do, these
are the options, what do you want?” I mean that is just
[terrible] because you’re the…expert, that’s what they’re
paying you for, “What would you do?” and you have to be
able to say, “I would—if this was my mum, that’s what I’d
do.” I think they should leave with a degree of certainty
about their treatment. …They can’t walk away thinking,
“…even the experts don’t know what to do.” That’s des-
perately wrong.
(Mr Halifax, Maxillofacial Surgeon, Interview)
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In this extract, Mr Halifax linked the provision of cer-
tainty to his status as a professional or expert.
Uncertainty, on the other hand, was seen as not
knowing what to do: he saw one of the roles of the MDT
meeting as creating certainty through a clear recommen-
dation. Thus, although the MDT is designed to bring
the various opinions of the expert members together in
a backstage setting, when these opinions are not aligned
with one another, the group faces difficulty and dis-
agreement on how to proceed. Here, Mr Halifax views
offering choice as potentially abandoning the patient
(‘these are the options, what do you want’), which then
acts a barrier to patient involvement.
The ‘evidential patient’
The desire of some MDT members to conceal uncer-
tainty and difference of opinion from the patient led to
a lot of the work associated with decision-making occur-
ring in the backstage MDT meeting, excluding the
patient. The patient is absent from the MDT discussion
and MDTs counteract this by creating an ‘evidential
patient’ in the backstage meeting using information
about them. The evidential patient was almost univer-
sally based on clinical information about the cancer size,
extent and spread; this was usually presented first and
thus forms the basis of the discussion. However, team
members recognised that this clinical information alone
did not provide a complete view of the patient:
You’re just making decisions based on scans and guide-
lines as opposed to an individual ever having had the
opportunity to explore not just their physical and psycho-
logical status, but their feelings about treatment…it
would be nice to have much more of a feel and a knowl-
edge of the patient before it gets to that MDT.
(Mrs Pope Speech and Language Therapist, Interview)
Mrs Pope expresses the difficulty in representing a
holistic view of a patient in a backstage setting. Her
statements reveal that the information provided often
does not include the patient’s lifestyle, context, values or
preferences. When information other than clinical
details of the tumour was available about the patient
(comorbidities, social situation, support network or even
stated values or preferences), this could have a signifi-
cant guiding effect on the discussion:
Mr Jones (ENT surgeon): He’s a very sort of straightfor-
ward sort of man, who doesn’t worry too much, but he
will probably cope with [the diagnosis] very well. But, he
needs a lot of radiotherapy
Dr Brown: What age is he?
Mr Jones: He’s 87, I mean he’s a very good 87.
(Stanley Wight, Observation, MDT meeting)
In this extract, it appears that there was a judgement
made by Mr Jones about the patient being a ‘very good
87’ years old. On one level, this provided more
information about the patient, and helped to form a
picture of the person that he is. On another level, it is a
judgement that is intended to sway the team in one dir-
ection, towards more radical management (this is what
the team recommended to the patient). These small but
important details often had vital guiding effects on the
tone of the discussion, which pushed the direction of
the MDT decision-making towards or away from specific
treatment options.
CONCLUSION
This detailed study is the first to explore the entire MDT
meeting and clinic decision process and has shown that
MDT decision-making presents significant barriers to
engaging with patient values and preferences, and thus
presents obstacles to delivering shared decision-making.
Although many members of the MDT have a clear view
of which treatment they consider to be ‘best’ in a given
clinical situation, they are not always in agreement with
one another. Any discussion of which treatment is ‘best’
depends on the values of the individual, and thus any
disagreements may reflect the differing values of the
MDT members. This only reinforces the argument for
making the values and preferences of the patient central
to the decision process. When team members disagree,
the MDT face difficulty in presenting this to the patient.
First, many MDT members feel that any disagreement
and difference of opinion in the MDT meeting should
be concealed from the patient. Second, MDT members
recognise that the clinician selected to present the treat-
ment choice to the patient may ‘frame’ their description
of the treatment options to fit their own view of best.
This makes the choice of clinician to deliver the treat-
ment choice a proxy for the recommendation itself.
Third, many MDT members see presenting treatment
options to the patient as abandoning them without guid-
ance from the MDT. This combination leads to a lot of
the work of decision-making (negotiating risks, trading
off function and survival, etc) occurring in the MDT
meeting, thus excluding the patient. Although MDT
members attempt to counteract this by introducing clin-
ical and non-clinical information about the patient into
the meeting (the ‘evidential patient’), this cannot be
construed as greater involvement of the patient in deci-
sions. The resultant recommendation, although per-
ceived as more ‘patient-centred’, cannot adequately
include the values and preferences of the patient and
thus does not constitute involvement of the patient.
Information about the social situation, character,
values or preferences of the patient is central to a perso-
nalised treatment decision. Information of this nature
holds particular power within the meeting, with a clin-
ician who has met and spoken to the patient holding
‘encountered authority’ over the decision-making
process.39 However, often only highly selected or very
limited information of this type can be available or
known and it can easily be selectively reported in order
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to bias or steer the discussion. Also, any attempt to
include information such as a patient preference as a
stable information commodity which can be passed from
person to person in the MDT meeting is problematic.
Patient preferences that are formed in life-threatening
situations are unlikely to be preformed or pre-existing40
and as a result are often unstable.41 Patients’ expressed
preferences are constructed during elicitation40 42 and
thus are labile, dynamic, reversible and sensitive to
option description: hence, they are the product of an
interaction.43 Furthermore, if the patients’ preferences
are indeed elicited, they may at first be uninformed and
taken at face value rather than explored and discussed.
In the current structure, the MDT faces difficulty in
moving from these ‘initial preferences’ to ‘informed pre-
ferences’44 as this cannot be performed in the absence
of the patient.
The MDT cannot make decisions that involve a patient
by introducing increasing amounts of information about
the patient into the backstage MDT meeting. Instead,
the MDT decision process should be structured to maxi-
mise the interaction between the members of the team
and the patient. Also, the current model of MDT
decision-making gives ample opportunity for clinicians
to discuss and negotiate aspects of the decision with
each other but does not afford patients the same oppor-
tunity. When patients’ processes of decision-making have
been explored, they have been found to be distributed
among people, places and information sources.45
Patients take the information which they have available
to them and share it with those important to them,
trading off and negotiating. Indeed, in this way, patients
behave in much the same way as the MDT members at
the MDT meeting.
This study represents the first ethnography of the
MDT meeting and the clinic combined and provides a
detailed analysis of the process of decision-making in
this setting. However, MDT structure and practice will
vary geographically, by disease and by patient group.
Although the MDT settings studied here may not pre-
cisely reflect the particular MDT set-up in other centres,
the concepts and challenges described may be applic-
able to other situations in which team decision-making
is used, especially in cancer care. Quantitative measures
of the MDT discussion have measured the ‘patient-
centredness’ of the backstage discussion by counting the
number of times patient information (demographics,
comorbidities, supportive needs, etc) are mentioned in
the MDT meeting. Not only has this often been found
lacking,46 47 but MDTs that include more information
about the patient in their meeting cannot be considered
to make ‘patient-centred’ recommendations. Previous
qualitative studies have described the predominance of
the biomedical model of disease in the MDT discussion
and the difficulties that MDTs face in not only represent-
ing the values or preferences of a patient in the back-
stage but also incorporating them in a meaningful way
into the discussion.31 32
Sharing decisions with patients is of central import-
ance to good quality, safe healthcare delivery.48
Although the introduction of the MDT has increased
the opportunity for professionals to be included in
cancer treatment decisions, opportunity for the patient
to be involved has been diminished. Many of the initial
proposed benefits of the MDT as proposed in the
Calman-Hine report may have been realised, but the sig-
nificant shift to recognising the importance of patient
involvement in decision-making seriously questions the
sustainability of the current model. Our results empha-
sise the major limitations inherent in the current mode
of team decision-making. If patients are to be effectively
involved in decision-making, there is a need for a sub-
stantial review of the approach in light of the recogni-
tion of the centrality of patients in decisions about their
own treatment. Now is the time to propose and test dif-
ferent models of decision-making for cancer (and other
MDT-based decisions), which retains the benefits of an
MDT approach but place the patient at the centre of
decision-making.
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